Viking Therapeutics, Inc. now looks poised to win the first round in a string of legal actions it has taken against Chinese firm Ascletis Pharma, Inc., in which the US biotech alleged infringement of trade secrets related to VK2809, a thyroid hormone receptor beta (THRβ) agonist it is developing for metabolic dysfunction-associated steatohepatitis (MASH).
Key Takeaways
-
Ascletis has received an unfavorable initial decision from the US International Trade Commission in a trade secrets dispute with Viking.
-
The initial determination could eventually lead to a US ban on importation of Ascletis' THRβ agonist ASC41 and ASC43F, a fixed-dose combination of ASC41 and an FXR agonist, for clinical trial purposes
On 4 October, Hong Kong-listed Ascletis received an initial determination from the US International Trade Commission (ITC) which could eventually lead to a ban on the importation into the US of two of its drug candidates for clinical trial purposes, according
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?